- Clinical Development – The Bahamas
Our lead product, AR-100, is an autologous mobilized peripheral blood cell therapy utilizing the Rejenevie™ proprietary immune restoration technology. This therapy is currently in Phase II studies at The Okyanos Center for Regenerative Medicine, in Freeport, Bahamas, under a protocol approved by the Bahamian National Stem Cell Ethics Committee (NSCEC). We are also in early development of an immune restoration therapy using a combination of factors isolated from young blood stem and immune cells (RJV-117, RJV-122). In parallel, we are developing an aged stromal vascular fraction (SVF) restoration therapy using either young mobilized blood (RJV-200) or the restorative factors that we have isolated (RJV-217, RJV-222). We anticipate these therapies being developed for all indications treated at Okyanos.
Rejenevie™ Therapeutics Product Pipeline
- Clinical Development – United States
In early 2020, we will begin our preclinical program to develop AR-100, as well as the proprietary combination of factors isolated from young mobilized blood stem and immune cells (RJV-17 and RJV-22). This pipeline will encompass both cell- and gene-based products, primarily developed as immunotherapies for a group of select oncology (liquid and solid tumor) and infectious disease indications. We are also exploring a unique group of downstream targets of RJV-17 and RJV-22, using a druggable approach.